{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T02:06:40Z","timestamp":1793844400081,"version":"4.6.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2018,7,9]],"date-time":"2018-07-09T00:00:00Z","timestamp":1531094400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Res"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1038\/s41390-018-0088-7","type":"journal-article","created":{"date-parts":[[2018,7,6]],"date-time":"2018-07-06T09:57:42Z","timestamp":1530871062000},"page":"520-526","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":66,"title":["Rituximab modulates T- and B-lymphocyte subsets and urinary CD80 excretion in patients with steroid-dependent nephrotic syndrome"],"prefix":"10.1038","volume":"84","author":[{"given":"Divya","family":"Bhatia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditi","family":"Sinha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pankaj","family":"Hari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shailaja","family":"Sopory","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Savita","family":"Saini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mamta","family":"Puraswani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Himanshi","family":"Saini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dipendra K","family":"Mitra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arvind","family":"Bagga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,7,9]]},"reference":[{"key":"88_CR1","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1038\/nrneph.2012.115","volume":"12","author":"LA Greenbaum","year":"2012","unstructured":"Greenbaum, L. A., Benndorf, R. & Smoyer, W. E. Childhood nephrotic syndrome-current and future therapies. Nat. Rev. Nephrol. 12, 445\u2013458 (2012).","journal-title":"Nat. Rev. Nephrol."},{"key":"88_CR2","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1007\/s00467-011-1947-1","volume":"27","author":"V Elie","year":"2012","unstructured":"Elie, V., Fakhoury, M., Deschenes, G. & Jacqz-Aigrain, E. Physiopathology of idiopathic nephrotic syndrome: Lessons from glucocorticoids and epigenetic perspectives. Pediatr. Nephrol. 27, 1249\u20131256 (2012).","journal-title":"Pediatr. Nephrol."},{"key":"88_CR3","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1038\/ki.1994.171","volume":"45","author":"EH Garin","year":"1994","unstructured":"Garin, E. H., Blanchard, D. K., Matsushima, K. & Djeu, J. Y. IL-8 production by peripheral blood mononuclear cells in nephrotic patients. Kidney Int. 45, 1311\u20131317 (1994).","journal-title":"Kidney Int."},{"key":"88_CR4","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/S1074-7613(01)00090-5","volume":"14","author":"JC Marie","year":"2001","unstructured":"Marie, J. C. et al. Mechanism of measles virus-induced suppression of inflammatory immune responses. Immunity 14, 69\u201379 (2001).","journal-title":"Immunity"},{"key":"88_CR5","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1038\/sj.ki.5000341","volume":"69","author":"V Audard","year":"2006","unstructured":"Audard, V. et al. Minimal change nephrotic syndrome and classical Hodgkin\u2019s lymphoma: report of 21 cases and review of the literature. Kidney Int. 69, 2251\u20132260 (2006).","journal-title":"Kidney Int."},{"key":"88_CR6","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1053\/j.ajkd.2009.03.019","volume":"54","author":"M Abdel-Hafez","year":"2009","unstructured":"Abdel-Hafez, M., Shimada, M., Lee, P. Y., Johnson, R. J. & Garin, E. H. Idiopathic nephrotic syndrome and atopy: is there a common link? Am. J. Kidney Dis. 54, 945\u2013953 (2009).","journal-title":"Am. J. Kidney Dis."},{"key":"88_CR7","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1007\/s00467-009-1194-x","volume":"24","author":"XS Shao","year":"2009","unstructured":"Shao, X. S. et al. The prevalence of Th17 cells and FOXP3 regulate T cells (Treg) in children with primary nephrotic syndrome. Pediatr. Nephrol. 24, 1683\u20131690 (2009).","journal-title":"Pediatr. Nephrol."},{"key":"88_CR8","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1159\/000350161","volume":"37","author":"L Wang","year":"2013","unstructured":"Wang, L. et al. The role of Th17\/IL-17 in the pathogenesis of primary nephrotic syndrome in children. Kidney Blood Press. Res. 37, 332\u2013345 (2013).","journal-title":"Kidney Blood Press. Res."},{"key":"88_CR9","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1038\/nm.3432","volume":"20","author":"N Komatsu","year":"2014","unstructured":"Komatsu, N. et al. Pathogenic conversion of Foxp3+ T cells into TH17 cells in autoimmune arthritis. Nat. Med. 20, 62\u201368 (2014).","journal-title":"Nat. Med."},{"key":"88_CR10","doi-asserted-by":"publisher","first-page":"26R","DOI":"10.1203\/PDR.0b013e31819e76c7","volume":"65","author":"EM Eisenstein","year":"2009","unstructured":"Eisenstein, E. M. & Williams, C. B. The T(reg)\/Th17 cell balance: a new paradigm for autoimmunity. Pediatr. Res. 65, 26R\u201331R (2009).","journal-title":"Pediatr. Res."},{"key":"88_CR11","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.jaut.2013.06.006","volume":"45","author":"LSK Walker","year":"2013","unstructured":"Walker, L. S. K. Treg and CTLA-4: two intertwining pathways to immune tolerance. J. Autoimmun. 45, 49\u201357 (2013).","journal-title":"J. Autoimmun."},{"key":"88_CR12","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1038\/ki.2010.143","volume":"78","author":"EH Garin","year":"2010","unstructured":"Garin, E. H. et al. Urinary CD80 is elevated in minimal change disease but not in focal segmental glomerulosclerosis. Kidney Int. 78, 296\u2013302 (2010).","journal-title":"Kidney Int."},{"key":"88_CR13","doi-asserted-by":"publisher","first-page":"7359","DOI":"10.1038\/sj.onc.1206939","volume":"22","author":"MR Smith","year":"2003","unstructured":"Smith, M. R. Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene 22, 7359\u20137368 (2003).","journal-title":"Oncogene"},{"key":"88_CR14","doi-asserted-by":"publisher","first-page":"3295","DOI":"10.1182\/blood-2006-05-021113","volume":"108","author":"MH Oers van","year":"2006","unstructured":"van Oers, M. H. et al. Rituximab maintenance improves clinical outcome of relapsed\/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: Results of a prospective randomized phase 3 inter group trial. Blood 108, 3295\u20133301 (2006).","journal-title":"Blood"},{"key":"88_CR15","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1002\/art.22505","volume":"56","author":"I Gunnarsson","year":"2007","unstructured":"Gunnarsson, I. et al. Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide-resistant proliferative lupus nephritis. Arthritis Rheum. 56, 1263\u20131272 (2007).","journal-title":"Arthritis Rheum."},{"key":"88_CR16","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1002\/art.30314","volume":"63","author":"FL Veerdonk Van de","year":"2011","unstructured":"Van de Veerdonk, F. L. et al. The anti-CD20 antibody rituximab reduces the Th17 cell response. Arthritis Rheum. 63, 1507\u20131516 (2011).","journal-title":"Arthritis Rheum."},{"key":"88_CR17","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1016\/S0140-6736(14)60541-9","volume":"384","author":"K Iijima","year":"2014","unstructured":"Iijima, K. et al. Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: A multicentre, double-blind, randomised, placebo-controlled trial. Lancet 384, 1273\u20131281 (2014).","journal-title":"Lancet"},{"key":"88_CR18","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1093\/ndt\/gfu267","volume":"30","author":"A Sinha","year":"2015","unstructured":"Sinha, A. et al. Efficacy and safety of rituximab in children with difficult-to-treat nephrotic syndrome. Nephrol. Dial. Transplant. 30, 96\u2013106 (2015).","journal-title":"Nephrol. Dial. Transplant."},{"key":"88_CR19","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.2215\/CJN.03470410","volume":"5","author":"A Gulati","year":"2010","unstructured":"Gulati, A. et al. Efficacy and safety of treatment with rituximab for difficult steroid-resistant and -dependent nephrotic syndrome. Clin. J. Am. Soc. Nephrol. 5, 2207\u20132212 (2010).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"88_CR20","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1038\/nrneph.2012.289","volume":"9","author":"A Sinha","year":"2013","unstructured":"Sinha, A. & Bagga, A. Rituximab therapy in nephrotic syndrome: implications for patients\u2019 management. Nat. Rev. Nephrol. 9, 154\u2013169 (2013).","journal-title":"Nat. Rev. Nephrol."},{"key":"88_CR21","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1002\/art.21617","volume":"54","author":"MJ Leandro","year":"2006","unstructured":"Leandro, M. J., Cambridge, G., Ehrenstein, M. R. & Edwards, J. C. Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis. Arthritis Rheum. 54, 613\u2013620 (2006).","journal-title":"Arthritis Rheum."},{"key":"88_CR22","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.2215\/CJN.11941115","volume":"11","author":"CY Chan","year":"2016","unstructured":"Chan, C. Y. et al. Lymphocyte activation markers as predictors of responsiveness to rituximab among patients with FSGS. Clin. J. Am. Soc. Nephrol. 11, 1360\u20131368 (2016). 8.","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"88_CR23","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1681\/ASN.2015050523","volume":"27","author":"M Colucci","year":"2016","unstructured":"Colucci, M. et al. B cell reconstitution after rituximab treatment in idiopathic nephrotic syndrome. J. Am. Soc. Nephrol. 27, 1811\u20131822 (2016).","journal-title":"J. Am. Soc. Nephrol."},{"key":"88_CR24","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1093\/rheumatology\/keu004","volume":"53","author":"F Ciccia","year":"2014","unstructured":"Ciccia, F. et al. Rituximab modulates IL-17 expression in the salivary glands of patients with primary Sjogren\u2019s syndrome. Rheumatology 53, 1313\u20131320 (2014).","journal-title":"Rheumatology"},{"key":"88_CR25","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1007\/s00467-009-1214-x","volume":"24","author":"C Araya","year":"2009","unstructured":"Araya, C. et al. T regulatory cell function in idiopathic minimal lesion nephrotic syndrome. Pediatr. Nephrol. 24, 1691\u20131698 (2009).","journal-title":"Pediatr. Nephrol."},{"key":"88_CR26","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1681\/ASN.V103529","volume":"10","author":"HK Yap","year":"1999","unstructured":"Yap, H. K. et al. Th1 and Th2 cytokine mRNA profiles in childhood nephrotic syndrome evidence for increased IL-13 mRNA expression in relapse. J. Am. Soc. Nephrol. 10, 529\u2013537 (1999).","journal-title":"J. Am. Soc. Nephrol."},{"key":"88_CR27","doi-asserted-by":"publisher","first-page":"2079","DOI":"10.1111\/j.1523-1755.2005.00664.x","volume":"68","author":"L Berre Le","year":"2005","unstructured":"Le Berre, L. et al. Renal macrophage activation and Th2 polarization precedes the development of nephrotic syndrome in Buffalo\/Mna rats. Kidney Int. 68, 2079\u20132090 (2005).","journal-title":"Kidney Int."},{"key":"88_CR28","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1681\/ASN.2006070710","volume":"18","author":"KW Lai","year":"2007","unstructured":"Lai, K. W. et al. Overexpression of interleukin-13 induces minimal-change-like nephropathy in rats. J. Am. Soc. Nephrol. 18, 1476\u20131485 (2007).","journal-title":"J. Am. Soc. Nephrol."},{"issue":"1","key":"88_CR29","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1007\/s10157-017-1415-8","volume":"22","author":"Mai Sato","year":"2017","unstructured":"Sato M., Kamei K., Ogura M., Ishikura K., Ito S. Relapse of nephrotic syndrome during post-rituximab peripheral blood B-lymphocyte depletion. Clin Exp Nephrol. 2017;22 https:\/\/doi.org\/10.1007\/s10157-017-1415-8 .","journal-title":"Clinical and Experimental Nephrology"},{"key":"88_CR30","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1093\/ndt\/gfr405","volume":"27","author":"AL Sellier-Leclerc","year":"2012","unstructured":"Sellier-Leclerc, A. L. et al. Rituximab in steroid-dependent idiopathic nephrotic syndrome in childhood-follow-up after CD19 recovery. Nephrol. Dial. Transplant. 27, 1083\u20131089 (2012).","journal-title":"Nephrol. Dial. Transplant."},{"key":"88_CR31","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1681\/ASN.2014080799","volume":"26","author":"P Ravani","year":"2015","unstructured":"Ravani, P. et al. Rituximab in children with steroid-dependent nephrotic syndrome: a multicenter, open-label, noninferiority, randomized controlled trial. J. Am. Soc. Nephrol. 26, 2259\u20132266 (2015).","journal-title":"J. Am. Soc. Nephrol."},{"key":"88_CR32","doi-asserted-by":"publisher","first-page":"e81836","DOI":"10.1172\/jci.insight.81836","volume":"2","author":"AH Kim","year":"2017","unstructured":"Kim, A. H. et al. B cell-derived IL-4 acts on podocytes to induce proteinuria and foot process effacement. JCI Insight 2, e81836 (2017).","journal-title":"JCI Insight"},{"key":"88_CR33","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1038\/pr.2016.200","volume":"81","author":"C Dossier","year":"2017","unstructured":"Dossier, C., Jamin, A. & Desch\u00eanes, G. Idiopathic nephrotic syndrome: the EBV hypothesis. Pediatr. Res. 81, 233\u2013239 (2017).","journal-title":"Pediatr. Res."},{"key":"88_CR34","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1111\/j.1749-6632.2009.04668.x","volume":"1173","author":"L Quartuccio","year":"2009","unstructured":"Quartuccio, L. et al. Long-term effects of rituximab in rheumatoid arthritis: clinical, biologic, and pharmacogenetic aspects. Ann. N. Y. Acad. Sci. 1173, 692\u2013700 (2009).","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"88_CR35","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s11302-015-9457-4","volume":"11","author":"A Bai","year":"2015","unstructured":"Bai, A. & Robson, S. Beyond ecto-nucleotidase: CD39 defines human Th17 cells with CD161. Purinergic Signal 11, 317\u2013319 (2015).","journal-title":"Purinergic Signal"},{"key":"88_CR36","doi-asserted-by":"publisher","first-page":"710","DOI":"10.2215\/CJN.08500815","volume":"11","author":"P Ravani","year":"2016","unstructured":"Ravani, P., Bonanni, A., Rossi, R., Caridi, G. & Ghiggeri, G. M. Anti-CD20 antibodies for idiopathic nephrotic syndrome in children. Clin. J. Am. Soc. Nephrol. 11, 710\u2013720 (2016).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"88_CR37","doi-asserted-by":"crossref","first-page":"3787","DOI":"10.4049\/jimmunol.143.11.3787","volume":"143","author":"K Hupp","year":"1989","unstructured":"Hupp, K., Siwarski, D., Mock, B. A. & Kinet, J. P. Gene mapping of the three subunits of the high affinity FcR for IgE to mouse chromosomes 1 and 19. J. Immunol. 143, 3787\u20133791 (1989).","journal-title":"J. Immunol."},{"key":"88_CR38","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1172\/JCI200420855","volume":"114","author":"TS Olson","year":"2004","unstructured":"Olson, T. S. et al. Expanded B-cell population blocks regulatory T cells and exacerbates ileitis in a murine model of Crohn disease. J. Clin. Invest. 114, 389\u2013398 (2004).","journal-title":"J. Clin. Invest."},{"key":"88_CR39","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1084\/jem.192.4.475","volume":"192","author":"V Moulin","year":"2000","unstructured":"Moulin, V. et al. B lymphocytes regulate dendritic cell (DC) function in vivo: increased interleukin 12 production by DCs from B cell-deficient mice results in T helper cell type 1 deviation. J. Exp. Med. 192, 475\u2013482 (2000).","journal-title":"J. Exp. Med."},{"key":"88_CR40","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1111\/ped.13255","volume":"59","author":"S Tsuji","year":"2017","unstructured":"Tsuji, S. et al. Regulatory T cells and CTLA-4 in idiopathic nephrotic syndrome. Pediatr. Int. 59, 643\u2013646 (2017).","journal-title":"Pediatr. Int."}],"container-title":["Pediatric Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41390-018-0088-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41390-018-0088-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41390-018-0088-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,3]],"date-time":"2023-09-03T15:23:58Z","timestamp":1693754638000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41390-018-0088-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,9]]},"references-count":40,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["88"],"URL":"https:\/\/doi.org\/10.1038\/s41390-018-0088-7","relation":{},"ISSN":["0031-3998","1530-0447"],"issn-type":[{"value":"0031-3998","type":"print"},{"value":"1530-0447","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,9]]},"assertion":[{"value":"4 April 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}